Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills | |
| Hyderabad - 500 034, Telangana, India | |
| CIN: L85195TG1984PLC004507 | |
| Tel: + 91 40 4900 2900 | |
| Fax: + 91 40 4900 2999 | |
| Email: mail@drreddys.com | |
| Web: www.drreddys.com |
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
This is to inform you that the United States Food & Drug Administration (USFDA) completed a GMP inspection at our API manufacturing facility (CTO-5) in Miryalaguda, Telangana, India. The inspection was conducted from 19th May, 2025 to 24th May, 2025. We have been issued a Form 483 with 2 observations, which we will address within the stipulated timeline.
This is for your information and record.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer & Head-CSR